sïParadigm Diagnostic Informatics

sïParadigm Diagnostic Informatics With 20 years of experience in the medical field. siParadigm has earned national accreditation from CLIA and CAP, as well as local licensing in several states.

siParadigm has built a legacy in laboratory testing solutions based on scientific excellence, innovation, and world-class service. At siParadigm, our priority is accuracy, integrity, and quality for our clients. Our experienced team of professionals use advanced technology to provide prompt results to ensure accuracy. We also have a strong commitment to quality in order to guarantee the best results for you.

Clearer answers can make a meaningful difference in cancer care. 🎗️Thank you, Jarurat Care Foundation, for recognizing s...
08/17/2026

Clearer answers can make a meaningful difference in cancer care. 🎗️

Thank you, Jarurat Care Foundation, for recognizing siParadigm’s commitment to providing advanced testing solutions for patients with rare and complex cancers.

🔬 Book a demo today: www.siparadigm.com

🤖 AI is shaping the future of cancer research.🧠August is World Cancer Support Month.The AACR highlights the growing pote...
08/10/2026

🤖 AI is shaping the future of cancer research.

🧠August is World Cancer Support Month.

The AACR highlights the growing potential of AI to accelerate cancer research, uncover new insights, and support advances in precision oncology.

🧠See if you're eligible for hereditary cancer testing:

https://www.neovare.com/en/questionnaire/front/Qw3OQ7GXj1o2CebvDlZtw68E

sïParadigm Diagnostic Informatics is proud to announce its selection as a Designated Laboratory for the National Cancer ...
03/13/2026

sïParadigm Diagnostic Informatics is proud to announce its selection as a Designated Laboratory for the National Cancer Institute (NCI) Combination Therapy Platform Trial with Molecular Analysis for Therapy Choice, known as ComboMATCH.

The NCI ComboMATCH initiative is a groundbreaking precision medicine study that aims to evaluate the effectiveness of new drug combinations for patients with advanced solid tumors based on the unique genetic makeup of their tumors.

Through this collaboration, patients who receive comprehensive solid tumor genomic testing with sïParadigm Diagnostic Informatics may be identified as potential candidates for various ComboMATCH treatment trials. These trials evaluate whether drug combinations directed by genetic testing can provide better outcomes for patients with locally advanced or advanced solid tumors.

About ComboMATCH

ComboMATCH is a precision medicine initiative sponsored by the National Cancer Institute (NCI), part of the National Institutes of Health. A unique initiative to test new combinations of cancer drugs guided by tumor biology, ComboMATCH aims to pair patients with locally advanced or advanced solid tumors with a therapy that has the potential to manage their cancer. The study will also assist physicians in devising more effective treatment strategies. ComboMATCH is led by the ECOG-ACRIN Cancer Research Group and the NCI through the National Clinical Trials Network (NCTN). ComboMATCH treatment trials are conducted by the NCI funded NCTN research groups in the United States.

These include the Alliance for Clinical Trials in Oncology, Children’s Oncology Group, ECOG-ACRIN Cancer Research Group, NRG Oncology, and SWOG Cancer Research Network. To learn more about ComboMATCH, visit:

www.ecog-acrin.org/combomatch and

www.cancer.gov/research/infrastructure/clinical-trials/featured/combomatch

Introducing: AI OncoNews—a forward-looking step in how we engage with innovation, oncology, and digital health.
01/21/2026

Introducing: AI OncoNews—a forward-looking step in how we engage with innovation, oncology, and digital health.

⭐There’s nothing more energizing than starting the week with purpose!⭐At sïParadigm Diagnostic Informatics we’re proud t...
01/05/2026

⭐There’s nothing more energizing than starting the week with purpose!

⭐At sïParadigm Diagnostic Informatics we’re proud to recognize the people behind the work that drives meaningful impact.

⭐Since joining , Emily Adams, our Account Manager, has been motivated by the opportunity to our clients with thoughtful solutions while growing alongside a team that values collaboration, , and continuous .

⭐Let this be your reminder today: when you lead with purpose, every becomes an opportunity.

As we step into 2026, sïParadigm is excited about new opportunities to grow innovate, and create impact.Wishing you a su...
01/01/2026

As we step into 2026, sïParadigm is excited about new opportunities to grow innovate, and create impact.

Wishing you a successful year ahead!

12/15/2025

At sïParadigm, we deliver fast, accurate results that empower better clinical decisions.

Our cutting-edge pathology services combine precision, speed, and reliability when it matters most.

Discover more at www.siparadigm.com

Fuel Your Week with Growth 🚀  Meet Omar — a shining example of what it means to grow with purpose.For over 5 years, he’s...
11/17/2025

Fuel Your Week with Growth 🚀

Meet Omar — a shining example of what it means to grow with purpose.
For over 5 years, he’s been an essential part of the siParadigm family, starting in Sales Support and now thriving in Billing. His journey is a reminder that embracing new challenges opens the door to new strengths, new skills, and new opportunities.

At siParadigm, we believe in career development, collaboration, and continuous improvement—and Omar embodies all of it with passion.

Here’s to inspiring journeys, bold transitions, and the power of never stopping your growth. 🌟

Address

25 Riverside Drive #2
Pine Brook, NJ
07058

Alerts

Be the first to know and let us send you an email when sïParadigm Diagnostic Informatics posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Practice

Send a message to sïParadigm Diagnostic Informatics:

Shortcuts

Share

Category